Abstract
Coagulation factor assays using one-stage methodology are widely used to measure factor levels for the purpose of detecting a deficiency, or to monitor replacement therapy. In this chapter, we focus on a method to measure Factor VIII coagulant activity (FVIII:C) by the one-stage assay (FVIII:C-1), with extra information provided to also allow this method to apply to Factor IX (FIX), Factor XI (FXI), and Factor XII (FXII). From the perspective of laboratory testing, these factors are components of the “intrinsic” coagulation pathway and are all measured in test systems based on the correction of the Activated Partial Thromboplastin Time (APTT). Factor activity is assessed by measuring the ability of an unknown sample to correct the prolonged APTT of factor-deficient plasma (deficient in the factor of interest), relative to the effect of a known calibrator. These assays are used for the diagnosis of the many causes of reduced factor levels, including those causing a prolonged APTT. It is important for laboratory staff to understand the impact of method variations, limitations, and result interpretation and these aspects are also discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, on behalf of the Factor VIII and Factor IX Subcommittee (2001) Definitions in haemophilia. Thromb Haemost 85:560
Preston FE, Kitchen S, Jennings I, Woods TAL, Makris M (2004) SSC/ISTH classification of haemophilia A: can haemophilia center laboratories achieve the new criteria? J Thromb Haemost 2:271–274
Peyvandi F, Oldenburg J, Friedman KD (2015) A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 14:248–261
Barrowcliffe TW, Raut S, Sands D, Hubbard AR (2001) Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 28:247–256
Duncan E, Collecutt M, Street A (2013) Nijmegen-Bethesda assay to measure factor VIII inhibitors. In: Monagle P (ed) Haemostasis: methods and protocols, methods in molecular biology, vol 992. Springer, London, UK, pp 321–333
Kitchen S, Hayward C, Negrier C, Dargaud Y (2010) New developments in laboratory diagnosis and monitoring. Haemophilia 16(Suppl. 5):61–66
Duncan EM, Rodgers SE, McRae SJ (2013) Diagnostic testing for mild Haemophilia a in patients with discrepant one-stage, two-stage and chromogenic FVIII:C assays. Semin Thromb Hemost 39:272–282
Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M, on behalf of the British Committee for Standards in Haematology (2013) Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 35:1–13
Kitchen S, Signer-Romero K, Key NS (2015) Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia 21:550–557
Favaloro EJ, Meijer P, Jennings I, Soufi J, Bonar RA, Kitchen DP et al (2013) Problems and solutions in laboratory testing for haemophilia. Semin Thromb Hemost 39:816–833
Hubbard AR, Hamill M, Beeharry M, Bevan SA, Heath AB, on behalf of the SSC Sub-committees on Factor VIII/Factor IX and von Willebrand factor of ISTH (2011) Value assignment of the WHO 6th international standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316). J Thromb Haemost 9:2100–2102
Favaloro EJ, Soltani S, McDonald J (2004) Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing. Am J Clin Pathol 122:686–692
Rodgers SE, Wong A, Gopal RD, Dale BJ, Duncan EM, McRae SJ (2014) Evaluation of pre-analytical variables in a commercial thrombin generation assay. Thromb Res 134:160–164
Westgard JO (2010) QC–the calculations. In: Basic QC practices, 3rd edn. Westgard QC, Inc., Madison, WI, pp 177–193. Chapter 13
Westgard JO (2003) Method validation: reference interval transference. In: Basic method validation, 2nd edn. Westgard QC, Inc., Madison, WI, pp 164–171. Chapter 15
Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L (2005) Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinolysis 16:597–605
Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ (2000) Type 1 von Willebrand disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 108:259–264
Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P (1987) Development of the human coagulation system in the full-term infant. Blood 70:165–172
Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A et al (2006) Developmental haemostasis: impact for clinical haemostasis laboratories. Thromb Haemost 95:362–372
Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R et al (2015) Inhibitor development and mortality in non-severe haemophilia A. J Thromb Haemost 13:1217–1225
Ay C, Thom K, Abu-Hamdeh F, Horvath B, Quehenberger P, Male C et al (2010) Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women. Haemophilia 16:111–117
Lyall H, Hill M, Westby J, Grimley C, Dolan G (2008) Tyr346-Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype – is this mild haemophilia A? Haemophilia 14:78–80
Verbruggen B, Meijer P, Novakova I, Van Heerde W (2008) Diagnosis of factor VIII deficiency. Haemophilia 14(Suppl 3):76–82
Mikaelsson M, Oswaldsson U, Sandberg H (1998) Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 4:646–650
Manco-Johnson MJ, Nuss R, Jacobson LJ (2000) Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med 136:74–79
Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K (2016) The effect of direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 48:60–71
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Duncan, E., Rodgers, S. (2017). One-Stage Factor VIII Assays. In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7196-1_20
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7194-7
Online ISBN: 978-1-4939-7196-1
eBook Packages: Springer Protocols